Immunotherapy in nasopharyngeal carcinoma: current status and unanswered questions
PD‑1 blockade significantly improves progression‑free survival in first‑line treatment of recurrent or metastatic nasopharyngeal carcinoma.
This review highlights that PD‑1 blockade improves survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma and identifies critical gaps in sequencing strategies, biomarker development, and resistance mechanisms that must be addressed to optimize therapy.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma
- Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region